Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (9)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

2022

  1. Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury

    Biomedicines, Vol. 10, Núm. 1

  2. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Lymphocyte Profile and Immune Checkpoint Expression in Drug-Induced Liver Injury: An Immunophenotyping Study

    Clinical Pharmacology and Therapeutics, Vol. 110, Núm. 6, pp. 1604-1612

2016

  1. Killer immunoglobulin-like receptor profiles are not associated with risk of amoxicillin-clavulanate-induced liver injury in Spanish patients

    Frontiers in Pharmacology, Vol. 7, Núm. AUG

2014

  1. Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohort

    PLoS ONE, Vol. 9, Núm. 4

2013

  1. HLA Alleles Influence the Clinical Signature of Amoxicillin-Clavulanate Hepatotoxicity

    PLoS ONE, Vol. 8, Núm. 7

  2. Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury

    Liver International, Vol. 33, Núm. 9, pp. 1378-1385

2010

  1. HLA alleles influence the occurrence and outcome of amoxicillin-clavulanate liver injury in Spanish patients

    TISSUE ANTIGENS